Compare
Savara Inc vs Phathom Pharmaceuticals, Inc. vs Verastem, Inc. vs Perspective Therapeutics, Inc.
| Latest fiscal year | Savara Inc SVRA | Phathom Pharmaceuticals, Inc. PHAT | Verastem, Inc. VSTM | Perspective Therapeutics, Inc. CATX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $175.11M | $30.91M | n/a |
| Revenue growth (YoY) | n/a | +216.9% | +209.1% | n/a |
| Gross margin | n/a | 87.1% | n/a | n/a |
| Operating margin | n/a | -91.4% | -550.3% | n/a |
| Net margin | n/a | -126.3% | -677.6% | n/a |
| Net income | -$118.84M | -$221.25M | -$209.47M | -$103.12M |
| EPS (Diluted) | -$0.53 | -$3.03 | -$3.02 | -$1.40 |
| Operating cash flow | -$101.04M | -$166.78M | -$137.51M | -$82.48M |
| Free cash flow | -$101.06M | -$167.00M | n/a | -$95.23M |
| Cash & equivalents | $33.18M | $129.97M | $204.99M | $30.63M |
| Total assets | $253.44M | $259.15M | $246.44M | $266.97M |
| Total liabilities | $50.30M | $697.32M | $189.25M | $59.94M |
| Shareholders' equity | $203.13M | -$438.17M | $57.20M | $207.03M |
| Return on year-end equity | -58.5% | n/a | -366.2% | -49.8% |
| Shares outstanding | 204.57M | 71.42M | 77.74M | 74.34M |
Revenue, most recent five fiscal years
| Fiscal year | Savara Inc | Phathom Pharmaceuticals, Inc. | Verastem, Inc. | Perspective Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $257.0K Ended 2020-12-31 | $175.11M Ended 2025-12-31 | $30.91M Ended 2025-12-31 | $1.43M Ended 2023-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $55.25M Ended 2024-12-31 | $10.00M Ended 2024-12-31 | $0 Ended 2022-12-31 |
| 2 years earlier | n/a | $682.0K Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $2.60M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $2.05M Ended 2021-12-31 | n/a |